Selling into a wave of new capacity being built by others: management describes its customers' own build-out spending as
The model's full reasoning — Q4 2023 call → NOWe need to determine if management explains current momentum and near-term trajectory chiefly by pointing to a wave of new building/equipping/capacity-creation by other parties, for which the company already supplies part, and that this build-out is early/intensifying. Let's analyze the transcript. The company is MannKind, which makes inhaled insulin (Afrezza), V-Go, and has partnerships with United Therapeutics for Tyvaso DPI (dry powder inhaler) manufacturing and royalties. Also has pipeline for NTM (clofazimine) and IPF (nintedanib). Key points: Management discusses Tyvaso DPI revenue growth, record production, and that they are making as much as they can. They mention that United Therapeutics is the customer, and they are manufacturing Tyvaso DPI for them. They also mention that Tyvaso DPI has two major trials (TETON 1 and TETON 2) that are 70% enrolled. They also mention that they are building a high-speed fill finish line for Tyvaso production. But the question is about "others are building" - i.e., counterparties putting new productive capability in place. Here, the company itself is building its own capacity (high-speed fill finish line). That is the company's own capacity expansion, not others. The question says: "NO if the building described is the company's OWN capacity expansion rather than that of outside parties." So that doesn't count. What about United Therapeutics? They are the customer for Tyvaso DPI. Are they building capacity? The transcript mentions that Tyvaso DPI is growing, but does it describe United Therapeutics building new capacity? Not really. It mentions that Tyvaso DPI has trials, but that's not building capacity. It's about demand. The company also mentions that they are making over 25 million doses and devices in 2024, and helped 25,000 patients. But that's their own production. The question is about a wave of building by others that the company supplies. For example, if the company supplies components to a semiconductor fab that is being built, that would be it. Here, the company is manufacturing Tyvaso DPI for United Therapeutics, but is United Therapeutics building new plants? Not mentioned. The transcript also discusses the pipeline: MNKD-101 (clofazimine) for NTM, and MNKD-201 (nintedanib) for IPF. These are the company's own products, not others' building. The company also discusses Afrezza and INHALE trials.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
TEL · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by others, that's early or intensif...YES The transcript shows management framing the company's momentum chiefly through a wave of external capacity creation: EV production growth (40% in 2023, expected continued growth next year, with Asia as driver), renewable energy adoption (wind/solar), and AI/cloud applications. They describe others (OEMs, installers 3rd parties) building new productive capability—new EV platforms, renewable sites, AI clusters—while TE already supplies into it via content outperformance and early ramps. Current business is real (sequential order growth, $1.3B pipeline, $100M+ incremental AI revenue). The wave is early/intensifying 2024–2025 (3–4 year programs, more phases ahead, destocking normalizing). This is presented as the primary secular driver offsetting cyclical weakness, not just consumption or pricing. Other elements (destocking, FX) are secondary. Thus all three conditions are met in substance.
ATI · Q1 2018 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building or capacity-creation by other parties, like customers, t...YES The transcript shows management attributing HPMC momentum chiefly to the "ongoing production ramp of next-generation jet engines at all of our major engine OEM customers" and the "industry is currently in the early phases of a multi-year production expansion." This describes OEMs creating new productive capacity through rate ramps and build growth for next generation engines. Management confirms current business from this wave with "next-generation product sales reached 48% of total jet engine product sales" and "65% increase in next-generation product sales," plus "seventh consecutive quarter of year-over-year margin expansion.
RDCM · Q4 2023 → YESThe question is about whether management explains the company's current momentum and near-term trajectory by pointing to a wave of new building, equipping, or capacity-creation by other parties (custo...YES The transcript shows management framing 2024 momentum around operators’ ongoing 5G standalone network build-outs (new productive capacity being created by customers), with RADCOM already supplying assurance software to those projects and the wave described as still early and accelerating. All three conditions are met in Eyal Harari’s prepared remarks and Q&A.